Should I buy or sell Lucid Diagnostics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lucid Diagnostics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LUCD shares. View LUCD analyst ratings or view top-rated stocks .

What is Lucid Diagnostics' stock price target for 2024?

2 brokers have issued 12-month price targets for Lucid Diagnostics' stock. Their LUCD share price targets range from $2.50 to $3.00. On average, they anticipate the company's stock price to reach $2.75 in the next year. This suggests a possible upside of 245.3% from the stock's current price. View analysts price targets for LUCD or view top-rated stocks among Wall Street analysts .

How have LUCD shares performed in 2024?

Lucid Diagnostics' stock was trading at $1.41 at the beginning of 2024. Since then, LUCD shares have decreased by 43.5% and is now trading at $0.7965. View the best growth stocks for 2024 here .

Are investors shorting Lucid Diagnostics?

Lucid Diagnostics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 441,000 shares, an increase of 91.1% from the March 15th total of 230,800 shares. Based on an average daily trading volume, of 141,600 shares, the days-to-cover ratio is currently 3.1 days. Currently, 3.8% of the company's shares are short sold. View Lucid Diagnostics' Short Interest .

When is Lucid Diagnostics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our LUCD earnings forecast .

How were Lucid Diagnostics' earnings last quarter?

Lucid Diagnostics Inc. (NASDAQ:LUCD) announced its earnings results on Tuesday, March, 26th. The company reported ($0.26) earnings per share for the quarter. The firm earned $1.04 million during the quarter. Lucid Diagnostics had a negative trailing twelve-month return on equity of 901.79% and a negative net margin of 2,169.07%. During the same period in the previous year, the company earned ($0.22) EPS.

When did Lucid Diagnostics IPO?

Lucid Diagnostics (LUCD) raised $75 million in an IPO on Thursday, October 14th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share.

How do I buy shares of Lucid Diagnostics?

Shares of LUCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:LUCD

Lucid Diagnostics (LUCD) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free LUCD Stock Alerts

$0.80

0.00 (0.00%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.77
▼
$0.81
50-Day Range: $0.80
▼
$1.37
52-Week Range: $0.76
▼
$1.85

Volume: 118,257 shs
Average Volume: 247,819 shs
Market Capitalization: $38.42 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.75

Get Lucid Diagnostics alerts:

Lucid Diagnostics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 245.3% Upside
$2.75 Price Target
Short Interest: Healthy
3.81% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.08
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.57 out of 5 stars

Medical Sector

592nd out of 911 stocks

Surgical & Medical Instruments Industry

65th out of 97 stocks

3.5

Analyst's Opinion

Consensus Rating
Lucid Diagnostics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Lucid Diagnostics has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.81% of the float of Lucid Diagnostics has been sold short.
Short Interest Ratio / Days to Cover
Lucid Diagnostics has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Lucid Diagnostics has recently increased by 91.07%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Lucid Diagnostics does not currently pay a dividend.
Dividend Growth
Lucid Diagnostics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LUCD.

1.7

News and Social Media Coverage

News Sentiment
Lucid Diagnostics has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Lucid Diagnostics this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for LUCD on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Lucid Diagnostics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Lucid Diagnostics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.80% of the stock of Lucid Diagnostics is held by insiders.
Percentage Held by Institutions
74.01% of the stock of Lucid Diagnostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Lucid Diagnostics is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Lucid Diagnostics is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Lucid Diagnostics Stock (NASDAQ:LUCD)

Lucid Diagnostics Inc., a commercial-stage medical diagnostics technology company, focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma in the United States. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. Lucid Diagnostics Inc. was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

LUCD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

LUCD Stock News Headlines

April 19, 2024 | investorplace.com

3 Penny Stocks That Could Make a Big Comeback by the End of Q2

April 15, 2024 | markets.businessinsider.com

Lucid Diagnostics: Strong Buy Rating with Significant Market Potential Despite Near-Term Losses

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

April 14, 2024 | americanbankingnews.com

Lucid Diagnostics' (LUCD) "Buy" Rating Reiterated at Needham & Company LLC

April 12, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Lucid Diagnostics Amidst Strong EsoGuard Testing Growth and Clear Reimbursement Path

April 12, 2024 | americanbankingnews.com

Lucid Diagnostics Inc. (NASDAQ:LUCD) Sees Large Increase in Short Interest

April 10, 2024 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Lucid Diagnostics (LUCD), Werewolf Therapeutics (HOWL)

April 10, 2024 | investing.com

Lucid Diagnostics holds Buy rating, and stock target on company's performance

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

March 28, 2024 | seekingalpha.com

Lucid Diagnostics Inc. (LUCD) Q4 2023 Earnings Call Transcript

March 28, 2024 | markets.businessinsider.com

Buy Rating for Lucid Diagnostics: Solid Test Volumes and Strategic Growth Initiatives Propel Market Position

March 28, 2024 | finance.yahoo.com

PAVmed Inc. (NASDAQ:PAVM) Q4 2023 Earnings Call Transcript

March 28, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Lucid Diagnostics Amid Strong Financials and Strategic Growth Initiatives

March 27, 2024 | finanznachrichten.de

PAVmed Inc.: PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results

March 27, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Lucid Diagnostics Amidst Growing Test Volume and Strategic Positioning for Medicare Reimbursement

March 27, 2024 | finance.yahoo.com

Lucid Diagnostics Inc. (NASDAQ:LUCD) Q4 2023 Earnings Call Transcript

March 27, 2024 | finance.yahoo.com

Q4 2023 Lucid Diagnostics Inc Earnings Call

March 25, 2024 | investorplace.com

LUCD Stock Earnings: Lucid Diagnostics Beats EPS, Misses Revenue for Q4 2023

March 25, 2024 | finance.yahoo.com

Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results

March 21, 2024 | markets.businessinsider.com

Lucid Diagnostics Gets Positive Data From Clinical Validation Study Of EsoGuard Esophageal DNA Test

March 21, 2024 | prnewswire.com

Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population

March 20, 2024 | finance.yahoo.com

Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference

February 21, 2024 | msn.com

Lucid Diagnostics target oesphageal cancer with early testing

February 16, 2024 | prnewswire.com

Lucid Diagnostics Provides Update Regarding World Trade Center Health Program

February 15, 2024 | finance.yahoo.com

Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony

February 15, 2024 | prnewswire.com

Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony

February 8, 2024 | finanznachrichten.de

Lucid Diagnostics Executes Contract to Provide EsoGuard Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors

See More Headlines

Receive LUCD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lucid Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/26/2024
Today: 4/20/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:LUCD
CUSIP: N/A
CIK: 1799011
Web: www.luciddx.com
Phone: 212-949-4319
Fax: N/A
Employees: 70
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $2.75
High Stock Price Target: $3.00
Low Stock Price Target: $2.50
Potential Upside/Downside: +245.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.27)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-52,670,000.00
Net Margins: -2,169.07%
Pretax Margin: -2,169.11%
Return on Equity: -901.79%
Return on Assets: -121.11%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.75
Quick Ratio: 0.74

Sales & Book Value

Annual Sales: $2.43 million
Price / Sales: 15.81
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.47) per share
Price / Book: -1.69

Miscellaneous

Outstanding Shares: 48,240,000
Free Float: 45,929,000
Market Cap: $38.42 million
Optionable: No Data
Beta: 1.63

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Dr. Lishan Aklog M.D. (Age 58)
Chairman & CEO
Mr. Shaun M. O'Neill M.B.A. (Age 41)
President & COO
Mr. Dennis M. McGrath CPA (Age 67)
Chief Financial Officer
Dr. Sanford D. Markowitz M.D.
Ph.D., Cofounder & Strategic Advisor, Member of the Medical Advisor Board
Dr. Joseph Willis M.D.
Cofounder, Strategic Advisor & Member of Medical Advisory Board
Dr. Amitabh Chak M.D.
Cofounder, Strategic Advisor & Member of Medical Advisory Board
Richard D. Yazbeck
Chief Technology Officer
Dr. Suman M. Verma M.D.
Ph.D., Chief Scientific Officer
Dr. Brian J. deGuzman M.D. (Age 59)
Chief Compliance Officer
Mr. Michael Adam Gordon (Age 50)
General Counsel & Secretary

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LUCD Stock Analysis - Frequently Asked Questions

Should I buy or sell Lucid Diagnostics stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lucid Diagnostics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LUCD shares.
View LUCD analyst ratings or view top-rated stocks.
What is Lucid Diagnostics' stock price target for 2024?: 2 brokers have issued 12-month price targets for Lucid Diagnostics' stock. Their LUCD share price targets range from $2.50 to $3.00. On average, they anticipate the company's stock price to reach $2.75 in the next year. This suggests a possible upside of 245.3% from the stock's current price.
View analysts price targets for LUCD or view top-rated stocks among Wall Street analysts.
How have LUCD shares performed in 2024?: Lucid Diagnostics' stock was trading at $1.41 at the beginning of 2024. Since then, LUCD shares have decreased by 43.5% and is now trading at $0.7965.
View the best growth stocks for 2024 here.
Are investors shorting Lucid Diagnostics?: Lucid Diagnostics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 441,000 shares, an increase of 91.1% from the March 15th total of 230,800 shares. Based on an average daily trading volume, of 141,600 shares, the days-to-cover ratio is currently 3.1 days. Currently, 3.8% of the company's shares are short sold.
View Lucid Diagnostics' Short Interest.

When is Lucid Diagnostics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our LUCD earnings forecast.
How were Lucid Diagnostics' earnings last quarter?: Lucid Diagnostics Inc. (NASDAQ:LUCD) announced its earnings results on Tuesday, March, 26th. The company reported ($0.26) earnings per share for the quarter. The firm earned $1.04 million during the quarter. Lucid Diagnostics had a negative trailing twelve-month return on equity of 901.79% and a negative net margin of 2,169.07%. During the same period in the previous year, the company earned ($0.22) EPS.
When did Lucid Diagnostics IPO?: Lucid Diagnostics (LUCD) raised $75 million in an IPO on Thursday, October 14th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share.
How do I buy shares of Lucid Diagnostics?: Shares of LUCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LUCD) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial